The text starts here.

News Release

FOR IMMEDIATE RELEASE
March 30, 2016

EISAI CO., LTD. AND AJINOMOTO CO., INC. ANNOUNCE ESTABLISHMENT OF GASTROINTESTINAL SPECIALTY PHARMA EA PHARMA CO., LTD. THROUGH THE INTEGRATION OF EISAI'S GASTROINTESTINAL DISEASE BUSINESS AND AJINOMOTO PHARMACEUTICALS CO., LTD.

Eisai Co., Ltd.
Ajinomoto Co., Inc.

Eisai Co., Ltd. (Headquarters: Tokyo, Representative Corporate Officer and CEO: Haruo Naito, “Eisai”) and Ajinomoto Co., Inc. (Headquarters: Tokyo, Representative Director, President and CEO: Takaaki Nishii, “Ajinomoto Co.”) announced today that based on the integration agreement signed and announced on October 15, 2015, the gastrointestinal specialty pharma EA Pharma Co., Ltd. (EA Pharma) will be established through the splitting off of a portion of Eisai's gastrointestinal disease treatment business and its subsequent succession by Ajinomoto Co.'s wholly-owned subsidiary AJINOMOTO PHARMACEUTICALS CO., LTD. (Headquarters: Tokyo, Representative Director and President and CEO: Takashi Nagamachi, “AJINOMOTO PHARMACEUTICALS”) via an absorption-type split as of April 1, 2016.

On April 1, 2016, Eisai's gastrointestinal disease business built up over more than 60 years and AJINOMOTO PHARMACEUTICALS, with amino acids at its core, will be integrated and commence business as EA Pharma, a gastrointestinal specialty pharma with a full value chain including research and development, production and logistics, sales and marketing. EA Pharma will strive toward realizing an Enterprise Architecture (EA) that will create new innovation from the combined knowledge of the two companies.


I.  Outline of EA Pharma
(1)  Company name EA Pharma Co., Ltd.
(2)  Date of establishment April 1, 2016
(3)  Location 1-1 Irifune 2-chome, Chuo-ku, Tokyo
(4)  Company representative Representative Director, President & CEO  Hajime Shimizu
(5)  Scope of business Pharmaceutical research and development, manufacture, sales, import and export of products
(6)  Capital 9,145 million yen
(7)  Number of employees Approximately 1,250

II.  EA Pharma's Corporate Philosophy and Vision
<Corporate Philosophy>
The gastrointestinal system is the vital link between food as a source of energy, and life itself. As a Japanese specialty pharma in the field of gastrointestinal disease, EA Pharma aims to be a human health care (hhc) company that can get close to patients suffering from gastrointestinal diseases through specialized research and development as well as a unique product lineup, and provide a wide range of solutions to patients and their families.

<Corporate Vision>
1. Specializing in gastrointestinal diseases such as inflammatory bowel disease (IBD), we will strive to address unmet medical needs through advanced research and development as well as focusing management resources on marketing activities from the patients' perspective.
2. All employees will conduct business activities that adhere strictly to all laws and ethics, and as a company, EA Pharma will aim to maximize social value to contribute to increasing corporate value for both the Eisai and Ajinomoto groups.

For reference
Product Lineup
Product nameDrug classification
AZULOXA® Tablets 15 mg, Granules 2.5% Anti-gastric ulcer agent
ARGIMATE® Anti-hyperammonemia agent
Argi-U® Injection / Granules Urea cycle disorder agent
ES-POLYTAMIN® Granules Essential amino acid formula
ELENTAL® Elemental diet
ELENTAL®P Elemental diet for neonate and infant
Enteronon®-R Antibiotic-resistant lactic acid bacteria
Stronger Neo-Minophagen® C Injection 5 mL, 20 mL /
P Injection 20 mL / Injection Syringe 20 mL, 40 mL
Liver disease / allergic disease treatment
Glycyron® Tablets Liver disease / allergic disease treatment
GLUCAGON for Inj. 1 unit “ITO” Synthetic glucagon
Selbex® Capsules 50 mg / Granules 10% Gastritis / gastric ulcer treatment
Teleminsoft® Suppositories 2 mg,10mg Bowel movement accelerating agent
Niflec® Oral cleaning solution for intestine
Pariet® Tablets 5 mg, 10 mg, 20 mg Proton pump inhibitor
Proctosedyl® Suppository, / Ointment Anti-hemorrhoid agent
HEPAN ED® Elemental diet for hepatic failure
MARZULENE® S COMBINATION GRANULES /
TABLETS 0.375 ES, 0.5 ES, 1.0 ES
Gastritis and peptic ulcer therapeutic agent
MOVIPREP® Oral cleansing solution for intestine
MORIHEPAMIN® Amino acid injection for hepatic failure
Rabecure® Pack 400,800 Helicobacter pylori infection treatment
Rabefine® Pack Helicobacter pylori infection treatment
LIVACT® Granules / JELLY Branched-chain amino acid preparation
LipaCreon® Granules 300 mg Packet / Capsules 150 mg Pancreatic digestive enzyme replacement
LENTINAN Anti-tumor agent

Co-promoted products
Product nameDrug classification
ACTONEL® Tablets 2.5 mg, 75 mg
[Licensee: Eisai Co., Ltd.]
Antiosteoporosis agent
ACTONEL® Tablets 17.5 mg
[Licensee: Eisai Co., Ltd.]
Antiosteoporosis agent,
Paget's disease agent
ATEDIO® Combination Tablets
[Licensee: MOCHIDA PHARMACEUTICAL CO., LTD.]
Selective AT1 receptor blocker
/ Long-acting calcium channel blocker
ATELEC® Tablets
[Licensee: MOCHIDA PHARMACEUTICAL CO.,LTD. ]
Long-acting calcium channel blocker
Amiyu® Granule
[Licensee: Yoshindo Inc.]
Essential amino acid preparation for renal failure
FASTIC® Tablets
[Licensee: MOCHIDA PHARMACEUTICAL CO., LTD.]
Fast-acting postprandial hypoglycemic agent

Food product lineup
Product nameClassification
INTESCLEAR® Medical foods
Diet for colon examination patients
MITHERAPIST® Functional foods
Superfine dispersed β -glucan

Corporate Logo
Corporate Logo(Japanese)    Corporate Logo(English)
(Japanese)    (English)


Design rationale

Color: The logo continues to use the colors of the Eisai corporate logo. “The red and blue colors in the Eisai Logo mark represent red oxygenated blood flowing through the arteries and blue deoxygenated blood flowing through the veins. Both types of blood flow incessantly through the heart, and our task is to prevent stagnation of the blood flow by promoting good health and improving quality of life.”
Shape: The image is the combination of the “E” from Eisai and “A” from Ajinomoto. Reflecting the desire to contribute to patients all over the world with EA Pharma products, the logo uses the earth as a design motif.


Media Inquiries
Public Relations Department
Eisai Co., Ltd.
TEL: +81-(0)3-3817-5120
Public Relations Department
Ajinomoto Co.,Inc.
TEL: +81-(0)3-5250-8180
*For media inquiries after April 1, please contact the following:
Management Strategy Department, PR Group
EA Pharma Co., Ltd.
TEL: +81-(0)3-6280-9802 / FAX: +81-(0)3-6280-9912

About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as “giving first thought to patients and their families and to increasing the benefits health care provides,” which we call our human health care (hhc) philosophy. With over 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our hhc philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs.
As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.
For more information about Eisai Co., Ltd., please visit www.eisai.com.

About Ajinomoto Co.
Ajinomoto Co. is a global manufacturer of high-quality seasonings, processed foods, beverages, amino acids, pharmaceuticals and specialty chemicals. For many decades Ajinomoto Co. has contributed to food culture and human health through wide-ranging application of amino acid technologies. Today, the company is becoming increasingly involved with solutions for improved food resources, human health and global sustainability. Founded in 1909 and now operating in 27 countries and regions, Ajinomoto Co. had net sales of JPY 1,006.6 billion (USD 9.17 billion) in fiscal 2014. For more about Ajinomoto Co. (TYO: 2802), visit www.ajinomoto.com.